Pharming Group Posts 27% Revenue Growth in 2025, Shifts to Profitability
Event summary
- Pharming Group reported a 27% year-over-year revenue increase to $376.1 million in 2025, driven by growth in RUCONEST® and Joenja®.
- Operating profit turned positive at $25.8 million in 2025, compared to a loss in 2024.
- Joenja® revenue surged 29% to $58.2 million, with U.S. patients on paid therapy increasing 25% to 120.
- The company identified 998 diagnosed APDS patients globally, expanding the potential market for Joenja®.
- Pharming provided 2026 revenue guidance of $405–$425 million, anticipating continued growth in both RUCONEST® and Joenja®.
The big picture
Pharming Group's shift to profitability in 2025 marks a strategic inflection point, driven by the strong performance of its core products, RUCONEST® and Joenja®. The company's ability to identify and treat rare diseases positions it in a growing niche within the biopharmaceutical sector. However, its long-term success hinges on navigating regulatory hurdles and sustaining pipeline momentum, particularly in expanding indications for its key therapies.
What we're watching
- Regulatory Milestones
- The pace at which Pharming secures regulatory approvals for Joenja® in pediatric indications and leniolisib in broader PID populations will determine its growth trajectory.
- Pipeline Execution
- Whether Pharming can sustain the momentum in its clinical pipeline, particularly with the Phase II readouts for leniolisib in PIDs and the FALCON study for napazimone, will be critical.
- Commercial Expansion
- How effectively Pharming can expand Joenja®'s market reach beyond the U.S., particularly in Europe and Japan, will impact its revenue diversification.
Related topics